Back to Search
Start Over
Utility of soluble triggering receptor expressed on myeloid cells-I (sTREM-I) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.
- Source :
- Innate Immunity; Oct2017, Vol. 23 Issue 7, p606-614, 9p
- Publication Year :
- 2017
-
Abstract
- The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire-Disability Index (HAQ-DI), patient's perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics. [ABSTRACT FROM AUTHOR]
- Subjects :
- RHEUMATOID arthritis
ULTRASONIC imaging
ANTINEOPLASTIC agents
INTERFERONS
CYTOKINES
Subjects
Details
- Language :
- English
- ISSN :
- 17534259
- Volume :
- 23
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Innate Immunity
- Publication Type :
- Academic Journal
- Accession number :
- 125730893
- Full Text :
- https://doi.org/10.1177/1753425917726862